- Home
- JBGS vs ADPT Comparison
JBGS vs ADPT Comparison
Compare JBGS & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBGS
- ADPT
- Stock Information
- Founded
- JBGS 2016
- ADPT 2009
- Country
- JBGS United States
- ADPT United States
- Employees
- JBGS N/A
- ADPT N/A
- Industry
- JBGS Real Estate Investment Trusts
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JBGS Real Estate
- ADPT Health Care
- Exchange
- JBGS Nasdaq
- ADPT Nasdaq
- Market Cap
- JBGS 1.2B
- ADPT 1.4B
- IPO Year
- JBGS 2017
- ADPT 2019
- Fundamental
- Price
- JBGS $17.53
- ADPT $9.58
- Analyst Decision
- JBGS Sell
- ADPT Buy
- Analyst Count
- JBGS 2
- ADPT 6
- Target Price
- JBGS $16.00
- ADPT $9.83
- AVG Volume (30 Days)
- JBGS 1.4M
- ADPT 2.5M
- Earning Date
- JBGS 04-29-2025
- ADPT 05-01-2025
- Dividend Yield
- JBGS 4.09%
- ADPT N/A
- EPS Growth
- JBGS N/A
- ADPT N/A
- EPS
- JBGS N/A
- ADPT N/A
- Revenue
- JBGS $520,825,000.00
- ADPT $189,527,000.00
- Revenue This Year
- JBGS N/A
- ADPT $25.00
- Revenue Next Year
- JBGS N/A
- ADPT $20.38
- P/E Ratio
- JBGS N/A
- ADPT N/A
- Revenue Growth
- JBGS N/A
- ADPT 8.61
- 52 Week Low
- JBGS $13.28
- ADPT $2.99
- 52 Week High
- JBGS $18.86
- ADPT $10.28
- Technical
- Relative Strength Index (RSI)
- JBGS 62.88
- ADPT 59.79
- Support Level
- JBGS $16.80
- ADPT $8.50
- Resistance Level
- JBGS $17.51
- ADPT $9.69
- Average True Range (ATR)
- JBGS 0.43
- ADPT 0.41
- MACD
- JBGS 0.05
- ADPT -0.01
- Stochastic Oscillator
- JBGS 62.08
- ADPT 77.52
About JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party asset management and real estate services. It generates maximum revenue from the commercial segment.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).